Home > Journals > Minerva Urologica e Nefrologica > Past Issues > Articles online first > Minerva Urologica e Nefrologica 2020 Mar 16

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

 

Minerva Urologica e Nefrologica 2020 Mar 16

DOI: 10.23736/S0393-2249.20.03615-2

Copyright © 2020 EDIZIONI MINERVA MEDICA

language: English

64CuCl2 PET/CT as a potential new imaging method in prostate cancer: illusion or reality?

Francesco CANTIELLO 1, Fabio CROCEROSSA 1 , Giuseppe L. CASCINI 2, Giorgio I. RUSSO 3,
Matteo FERRO 4, Sebastiano CIMINO 3, Giuseppe LUCARELLI 5, Rocco DAMIANO 1

1 Department of Urology, Magna Graecia University of Catanzaro, Catanzaro, Italy; 2 Diagnostic Imaging, Nuclear Medicine Unit, Magna Graecia University of Catanzaro, Catanzaro, Italy; 3 Department of Urology, University of Catania, Catania, Italy; 4 Department of Urology, European Institute of Oncology, Milan, Italy; 5 Department of Urology and Kidney Transplantation, University of Bari, Bari, Italy


PDF


Copper (Cu) is an essential element for many cellular functions, including proliferation and angiogenesis. High serum Cu levels have been demonstrated in patients with neoplasia as well as high intra-tumoral Cu levels have been reported. Preclinical and clinical evidences suggest its use, in the form of 64Copper chloride (64CuCl2), as metabolic PET tracer in cancer diagnosis and therapy. Specifically, the use of 64CuCl2 in human Prostate Cancer (PCa) evidenced a high uptake of 64CuCl2 in tumoral prostate and involved regional lymph nodes in a staging setting and high sensitivity for local recurrence and lymph nodes detection in restaging, indicating its great potential. However, further and more solid clinical evidences are needed. On the other hand, 64CuCl2 seems to be a promising radiometabolic drug with great cytotoxic abilities on PCa cells. We have collected the most recent and relevant findings on its potential uses and limitations for the study and treatment of PCa, together with its possible translation in daily clinical practice.


KEY WORDS: 64CuCl2 PET/CT; Prostate cancer; Nuclear medicine; Staging; Re-staging; Radiotherapy

top of page